Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TPR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TPR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TPR_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TPR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TPR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TPR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TPR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TPR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TPR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TPR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004593619 | Prostate | Tumor | negative regulation of phosphate metabolic process | 124/3246 | 441/18723 | 9.08e-09 | 3.44e-07 | 124 |
GO:001081018 | Prostate | Tumor | regulation of cell-substrate adhesion | 73/3246 | 221/18723 | 9.68e-09 | 3.62e-07 | 73 |
GO:001056319 | Prostate | Tumor | negative regulation of phosphorus metabolic process | 124/3246 | 442/18723 | 1.05e-08 | 3.88e-07 | 124 |
GO:005067815 | Prostate | Tumor | regulation of epithelial cell proliferation | 110/3246 | 381/18723 | 1.32e-08 | 4.82e-07 | 110 |
GO:009013217 | Prostate | Tumor | epithelium migration | 105/3246 | 360/18723 | 1.57e-08 | 5.62e-07 | 105 |
GO:007048218 | Prostate | Tumor | response to oxygen levels | 102/3246 | 347/18723 | 1.62e-08 | 5.75e-07 | 102 |
GO:009013017 | Prostate | Tumor | tissue migration | 106/3246 | 365/18723 | 1.73e-08 | 6.10e-07 | 106 |
GO:001063117 | Prostate | Tumor | epithelial cell migration | 104/3246 | 357/18723 | 1.97e-08 | 6.91e-07 | 104 |
GO:009031614 | Prostate | Tumor | positive regulation of intracellular protein transport | 57/3246 | 160/18723 | 2.01e-08 | 7.03e-07 | 57 |
GO:003460518 | Prostate | Tumor | cellular response to heat | 32/3246 | 69/18723 | 2.21e-08 | 7.68e-07 | 32 |
GO:003166818 | Prostate | Tumor | cellular response to extracellular stimulus | 78/3246 | 246/18723 | 2.34e-08 | 8.08e-07 | 78 |
GO:000166718 | Prostate | Tumor | ameboidal-type cell migration | 130/3246 | 475/18723 | 2.36e-08 | 8.09e-07 | 130 |
GO:005189315 | Prostate | Tumor | regulation of focal adhesion assembly | 31/3246 | 66/18723 | 2.52e-08 | 8.33e-07 | 31 |
GO:009010915 | Prostate | Tumor | regulation of cell-substrate junction assembly | 31/3246 | 66/18723 | 2.52e-08 | 8.33e-07 | 31 |
GO:003253518 | Prostate | Tumor | regulation of cellular component size | 109/3246 | 383/18723 | 3.56e-08 | 1.12e-06 | 109 |
GO:000315815 | Prostate | Tumor | endothelium development | 50/3246 | 136/18723 | 4.60e-08 | 1.42e-06 | 50 |
GO:004682216 | Prostate | Tumor | regulation of nucleocytoplasmic transport | 42/3246 | 106/18723 | 4.65e-08 | 1.43e-06 | 42 |
GO:004544614 | Prostate | Tumor | endothelial cell differentiation | 45/3246 | 118/18723 | 6.08e-08 | 1.80e-06 | 45 |
GO:000155815 | Prostate | Tumor | regulation of cell growth | 115/3246 | 414/18723 | 6.40e-08 | 1.88e-06 | 115 |
GO:007084915 | Prostate | Tumor | response to epidermal growth factor | 25/3246 | 49/18723 | 7.26e-08 | 2.04e-06 | 25 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa05216 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa052161 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa050142 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
hsa050143 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
hsa050144 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa052162 | Colorectum | MSS | Thyroid cancer | 21/1875 | 37/8465 | 4.98e-06 | 6.00e-05 | 3.68e-05 | 21 |
hsa050145 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa052163 | Colorectum | MSS | Thyroid cancer | 21/1875 | 37/8465 | 4.98e-06 | 6.00e-05 | 3.68e-05 | 21 |
hsa050148 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
hsa052164 | Colorectum | FAP | Thyroid cancer | 12/1404 | 37/8465 | 1.33e-02 | 4.46e-02 | 2.71e-02 | 12 |
hsa050149 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
hsa052165 | Colorectum | FAP | Thyroid cancer | 12/1404 | 37/8465 | 1.33e-02 | 4.46e-02 | 2.71e-02 | 12 |
hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa0521610 | Endometrium | AEH | Thyroid cancer | 12/1197 | 37/8465 | 3.68e-03 | 2.14e-02 | 1.56e-02 | 12 |
hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa0521615 | Endometrium | AEH | Thyroid cancer | 12/1197 | 37/8465 | 3.68e-03 | 2.14e-02 | 1.56e-02 | 12 |
hsa0501425 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
hsa0521625 | Endometrium | EEC | Thyroid cancer | 13/1237 | 37/8465 | 1.51e-03 | 9.55e-03 | 7.12e-03 | 13 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TPR | SNV | Missense_Mutation | novel | c.1112N>G | p.Ser371Cys | p.S371C | P12270 | protein_coding | deleterious(0) | possibly_damaging(0.785) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TPR | SNV | Missense_Mutation | | c.4793N>C | p.Arg1598Pro | p.R1598P | P12270 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0YF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Arimidex | SD |
TPR | SNV | Missense_Mutation | novel | c.2186A>T | p.Gln729Leu | p.Q729L | P12270 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
TPR | SNV | Missense_Mutation | | c.6664G>A | p.Val2222Met | p.V2222M | P12270 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TPR | SNV | Missense_Mutation | | c.3061N>C | p.Asp1021His | p.D1021H | P12270 | protein_coding | deleterious(0) | benign(0.188) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TPR | SNV | Missense_Mutation | | c.4888G>A | p.Glu1630Lys | p.E1630K | P12270 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TPR | SNV | Missense_Mutation | rs533241956 | c.5459C>T | p.Ser1820Leu | p.S1820L | P12270 | protein_coding | tolerated(0.05) | benign(0.288) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TPR | SNV | Missense_Mutation | | c.4647N>T | p.Lys1549Asn | p.K1549N | P12270 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TPR | SNV | Missense_Mutation | novel | c.5465N>A | p.Thr1822Asn | p.T1822N | P12270 | protein_coding | deleterious(0) | possibly_damaging(0.852) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TPR | SNV | Missense_Mutation | novel | c.1503N>T | p.Arg501Ser | p.R501S | P12270 | protein_coding | tolerated(0.19) | possibly_damaging(0.838) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |